Work

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Year: 2003

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: John Murren, Manuel Modiano, Caroline Clairmont, Paula Lambert, Niramol Savaraj, Terry Doyle, Mario Sznol

Institutions: Yale Cancer Center, Vion Pharmaceuticals (United States)

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2099007229

FWCI: 1.508

Cites: 23

Cited by: 108

Related to: 10